Emotion processing in treatment-resistant schizophrenia patients treated with clozapine: An fMRI study

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 377-380

  Potvin, Stéphane ^a,b   Tikàsz, Andràs ^a,b   Lungu, Ovidiu ^b,c,d   Dumais, Alexandre ^a,b,e   Stip, Emmanuel ^a,b,f   Mendrek, Adrianna ^a,g  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE   (Canada)

^d Donald Berman Maimonides Geriatric Center   (Canada)

^e Institut Philippe Pinel de Montreal   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g BISHOP'S UNIVERSITY   (Canada)

Author keywords

Clozapine; Emotion; FMRI; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OXYGEN;

ADULT; ARTICLE; BRAIN REGION; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DORSOMEDIAL PREFRONTAL CORTEX; EMOTIONALITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; IMAGE ANALYSIS; MID CINGULATE GYRUS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SUPERIOR FRONTAL GYRUS; TREATMENT RESPONSE; BLOOD; BRAIN; COMPLICATION; DRUG EFFECTS; EMOTION; FEMALE; IMAGE PROCESSING; MALE; MOOD DISORDERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; VASCULARIZATION;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; EMOTIONS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MOOD DISORDERS; OXYGEN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84942374280     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.07.046     Document Type: Article

References (31)

1. Bourque J., Mendrek A., Durand M., Lakis N., Lipp O., Stip E., Lalonde P., Grignon S., Potvin S. Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. Psychiatry Res. 2013, 214(1):24-32.
2. Boynton G.M., Engel S.A., Glover G.H., Heeger D.J. Linear systems analysis of functional magnetic resonance imaging in human V1. J. Neurosci. 1996, 16(13):4207-4221.
3. Coutlee C.G., Huettel S.A. The functional neuroanatomy of decision making: prefrontal control of thought and action. Brain Res. 2012, 1428:3-12.
4. Eickhoff S.B., Laird A.R., Fox P.T., Bzdok D., Hensel L. Functional Segregation of the Human Dorsomedial Prefrontal Cortex 2014.
5. Elkis H. Treatment-resistant schizophrenia. Psychiatr. Clin. N. Am. 2007, 30(3):511-+.
6. Frank D.W., Dewitt M., Hudgens-Haney M., Schaeffer D.J., Ball B.H., Schwarz N.F., Hussein A.A., Smart L.M., Sabatinelli D. Emotion regulation: quantitative meta-analysis of functional activation and deactivation. Neurosci. Biobehav. Rev. 2014, 45:202-211.
7. Hall J., Whalley H.C., McKirdy J.W., Romaniuk L., McGonigle D., McIntosh A.M., Baig B.J., Gountouna V.E., Job D.E., Donaldson D.I., Sprengelmeyer R., Young A.W., Johnstone E.C., Lawrie S.M. Overactivation of fear systems to neutral faces in schizophrenia. Biol. Psychiatry 2008, 64(1):70-73.
8. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia 1987, 13(2):261-276.
9. Kennedy J.L., Altar C.A., Taylor D.L., Degtiar I., Hornberger J.C. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int. Clin. Psychopharmacol. 2014, 29(2):63-76.
10. Kubera K.M., Sambataro F., Vasic N., Wolf N.D., Frasch K., Hirjak D., Thomann P.A., Wolf R.C. Source-based morphometry of gray matter volume in patients with schizophrenia who have persistent auditory verbal hallucinations. Prog. Neuro-Psychopharmacol. 2014, 50:102-109.
11. Lakis N., Mendrek A. Individuals diagnosed with schizophrenia assign emotional importance to neutral stimuli: an FMRI study. ISRN Psychiatry 2013, 965428.
12. Lang P.J., Bradley M.M., Cuthbert B.N. International affective picture system (IAPS): affective ratings of pictures and instruction manual. Technical Report A-8 2008, University of Florida, Gainesville, FL.
13. Leucht S., Corves C., Arbter D., Engel R.R., Li C.B., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
14. Li H., Chan R.C., McAlonan G.M., Gong Q.Y. Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophr. Bull. 2010, 36(5):1029-1039.
15. Lungu O., Barakat M., Laventure S., Debas K., Proulx S., Luck D., Stip E. The incidence and nature of cerebellar findings in schizophrenia: a quantitative review of fMRI literature. Schizophr. Bull. 2013, 39(4):797-806.
16. Molina V., Sanz J., Sarramea F., Palomo T. Marked hypofrontality in clozapine-responsive patients. Pharmacopsychiatry 2007, 40(4):157-162.
17. Molina V., Tamayo P., Montes C., De Luxán A., Martin C., Rivas N., Sancho C., Domínguez-Gil A. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(4):948-954.
18. Muscatello M.R., Bruno A., De Fazio P., Segura-Garcia C., Pandolfo G., Zoccali R. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert. Opin. Pharmacother. 2014, 15(16):2329-2345.
19. Nakajima S., Takeuchi H., Plitman E., Fervaha G., Gerretsen P., Caravaggio F., Chung J.K., Iwata Y., Remington G., Graff-Guerrero A. Neuroimaging findings in treatment-resistant schizophrenia: a systematic review: lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr. Res. 2015, 164(1-3):164-175.
20. Nenadic I., Yotter R.A., Sauer H., Gaser C. Cortical surface complexity in frontal and temporal areas varies across subgroups of schizophrenia. Hum. Brain Mapp. 2014, 35(4):1691-1699.
21. Penny W.D., Holmes A.J. Random-effects analysis. Human Brain Function 2003, Academic Press, London. 2nd ed. R.S.J. Frackowiak, K.J. Friston, C. Frith, R. Dolan, K.J. Friston, C.J. Price, S. Zeki, J. Ashburner, W.D. Penny (Eds.).
22. Savla G.N., Vella L., Armstrong C.C., Penn D.L., Twamley E.W. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr. Bull. 2013, 39(5):979-992.
23. Shackman A.J., Salomons T.V., Slagter H.A., Fox A.S., Winter J.J., Davidson R.J. The integration of negative affect, pain and cognitive control in the cingulate cortex. Nat. Rev. Neurosci. 2011, 12(3):154-167.
24. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description 1992, 49:624-629. 8.
25. Stoodley C.J., Schmahmann J.D. Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies. NeuroImage 2009, 44(2):489-501.
26. Suzuki T., Remington G., Mulsant B.H., Rajji T.K., Uchida H., Graff-Guerrero A., Mamo D.C. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr. Res. 2011, 133(1-3):54-62.
27. Talairach J., Tournoux P. Co-planar stereotaxic atlas of the human brain. Thieme Medical, Stuttgart, Germany 1988.
28. Vercammen A., Morris R., Green M.J., Lenroot R., Kulkarni J., Carr V.J., Weickert C.S., Weickert T.W. Reduced neural activity of the prefrontal cognitive control circuitry during response inhibition to negative words in people with schizophrenia. J. Psychiatry Neurosci. 2012, 37(6):379-388.
29. Ward B. Deconvolution analysis of fMRI time series data. AFNI 3dDeconvolve Documentation 2000, Medical College of Wisconsin, (doi:http://afni.nimh.nih.gov/pub/dist/doc/manual/Deconvolvem.pdf).
30. Wechsler abbreviated scale of intelligence (WASI) Norwegian Manual Supplement 2007, Harcourt Assessment, Inc., Stockholm, Sweden.
31. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.